Foresight Global Investors Inc. Has $17.38 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

Foresight Global Investors Inc. reduced its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 258,028 shares of the company’s stock after selling 9,702 shares during the quarter. AstraZeneca accounts for approximately 10.0% of Foresight Global Investors Inc.’s portfolio, making the stock its 2nd largest holding. Foresight Global Investors Inc.’s holdings in AstraZeneca were worth $17,378,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Anchor Investment Management LLC bought a new stake in shares of AstraZeneca in the fourth quarter worth about $26,000. Compagnie Lombard Odier SCmA bought a new position in shares of AstraZeneca during the fourth quarter valued at approximately $27,000. Nemes Rush Group LLC lifted its stake in AstraZeneca by 375.6% in the third quarter. Nemes Rush Group LLC now owns 428 shares of the company’s stock worth $29,000 after acquiring an additional 338 shares during the period. LWM Advisory Services LLC bought a new stake in AstraZeneca in the third quarter valued at $35,000. Finally, Arlington Trust Co LLC purchased a new position in AstraZeneca during the 4th quarter valued at $37,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 0.8 %

NASDAQ:AZN traded up $0.64 during trading hours on Thursday, reaching $77.61. 2,972,096 shares of the company traded hands, compared to its average volume of 6,319,074. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $77.64. The stock has a market capitalization of $240.63 billion, a P/E ratio of 38.04, a P/E/G ratio of 1.38 and a beta of 0.47. The business’s 50-day moving average price is $69.01 and its two-hundred day moving average price is $66.58. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). The firm had revenue of $12.02 billion during the quarter, compared to the consensus estimate of $12.07 billion. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.69 EPS. Analysts predict that AstraZeneca PLC will post 4.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. BMO Capital Markets upped their target price on AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday, April 26th. Finally, Morgan Stanley assumed coverage on AstraZeneca in a research note on Tuesday, January 23rd. They issued an “overweight” rating for the company. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $81.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.